Brief: Annexon- Outlines 2024 Priorities With Late-Stage Clinical Milestones Across Upstream Complement Portfolio

Annexon

08/01/2024 22:14

Jan 8 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON-OUTLINES 2024 PRIORITIES WITH LATE-STAGE CLINICAL
MILESTONES ACROSS UPSTREAM COMPLEMENT PORTFOLIO FOR AUTOIMMUNE,
OPHTHALMIC & NEURODEGENERATIVE DISEASES
    * ANNEXON INC - ANX005 PHASE 3 PIVOTAL DATA IN
GUILLAIN-BARRÉ
SYNDROME (GBS) ON TRACK FOR FIRST HALF OF 2024
    * ANNEXON INC - ANX007 GLOBAL PIVOTAL PROGRAM IN GEOGRAPHIC
ATROPHY (GA) TO INITIATE MID-2024
    * ANNEXON - CLINICAL PROOF-OF-CONCEPT STUDY OF ANX1502
FIRST-IN-KIND ORAL SMALL MOLECULE INHIBITOR OF CLASSICAL PATHWAY
TO INITIATE IN H1 2024
    * ANNEXON INC - $125 MILLION FINANCING EXTENDS OPERATING
RUNWAY
INTO SECOND QUARTER 2026

Further company coverage:  ANNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))